The startup develops artificial intelligence tools that analyze the genetic code of biological parents to identify risks associated with congenital diseases, infertility, and hereditary cancers. By providing precise genetic insights, the technology enhances cancer care and bioethical standards for patients in Latin America.
Funding
Funding not disclosed
Founders
Product
Problem
Congenital diseases, infertility, and hereditary cancers pose significant health risks, often requiring extensive and costly diagnostic procedures. Current methods for assessing these risks may lack the precision needed for early detection and personalized treatment plans, particularly in diverse populations. Access to advanced genetic screening and counseling services remains limited, especially in regions like Latin America.
Solution
This startup offers AI-powered tools that analyze the genetic code of prospective parents to identify potential risks associated with congenital diseases, infertility, and hereditary cancers. By leveraging advanced algorithms, the technology provides precise genetic insights, enabling proactive healthcare management and informed decision-making. The platform aims to enhance cancer care and improve bioethical standards by offering accessible and comprehensive genetic analysis. The AI-driven approach facilitates early detection, personalized treatment strategies, and improved patient outcomes.
Target Audience
The primary target audience includes prospective parents, healthcare providers, oncologists, and clinical geneticists in Latin America seeking advanced genetic screening and personalized risk assessment tools.
Features
- AI-powered analysis of genetic code for risk assessment
- Identification of genetic predispositions to congenital diseases
- Screening for infertility-related genetic factors
- Detection of hereditary cancer risks
- Personalized insights for proactive healthcare management